QIAGEN Reports Second Quarter 2011 Results

Hilden/ Venlo, The Netherlands (ots) -

- Improving results in second quarter of 2011: Net sales grow 7%
(+1% CER) to $282.2 million, adjusted EPS rises to $0.23 and free
cash flow jumps 31% to $37.8 million

- Expansion strategy in 2011 achieves progress toward accelerating
growth in 2012:

- Strengthening leadership in Personalized Healthcare: First U.S.
submission completed for KRAS biomarker as companion
diagnostic; Ipsogen acquisition adds portfolio of blood cancer
assays

- Cellestis acquisition on track for completion in late August,
provides access to novel "pre-molecular" technology
commercialized with leading test for latent TB

- QIAsymphony automation platform achieves installed base of more
than 475 worldwide, driven by increasing adoption of full
QIAsymphony RGQ system

- QIAGEN updates 2011 expectations for acquisitions and
challenging market conditions

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today
announced results of operations for the second quarter and first
half of 2011, delivering improved performance and solid gains in
free cash flow.

Net sales in the second quarter rose 7% (+1% at constant
exchange rates, or CER) to $282.2 million from the second quarter
of 2010. Adjusted operating income grew 8% to $78.7 million, as the
adjusted operating income margin remained steady at 28% of
net sales. Adjusted diluted earnings per share rose to $0.23 in
the second quarter from $0.22 in the same period of 2010. Free cash
flow in the second quarter improved 31% to $37.8 million over
the year-ago period.

QIAGEN also updated its expectations for 2011 to incorporate
the impact of acquisitions of Cellestis and Ipsogen as well as based
on the adverse impact of continued challenging market conditions.

"We are making broad progress in our strategy to expand in 2011,
a year that has proven to be more challenging than anticipated,
in order to accelerate growth in 2012. We delivered improved results
in the second quarter amid continued weak economic conditions. We
have achieved key milestones, particularly the completion of our
first U.S. submission for our therascreen KRAS RGQ assay for use
as a companion diagnostic with an anticancer medicine. We
expect a second, separate FDA submission to be done shortly for
this assay for use with another anticancer medicine. The addition
of Cellestis will expand our product range into latent disease
detection, while Ipsogen's blood cancer test portfolio enhances
our leadership in cancer profiling and companion diagnostics
in personalized healthcare. The rollout of QIAsymphony has
reached more than 475 installed systems, driven by growing
customer appreciation of the QIAsymphony RGQ version launched in
late 2010," said Peer Schatz, Chief Executive Officer of QIAGEN
N.V. "Expectations for 2011 have been updated to include these
acquisitions as well as moderate growth prospects in the second
half. We expect growth to be above levels in the first half
of 2011, but lower than initially anticipated due to ongoing
challenging economic conditions in the U.S. and Europe. We are
intensifying our focus on growth and innovation, and are
confident that QIAGEN is well-positioned for sustained business
expansion."

Second Quarter 2011 Results

| | | |Change |
|in $ millions, except per |Q2 2011 |Q2 2010 |$ |CER |
|share information | | | | |
|Net sales |282.2 |262.7 |7% |1% |
|Operating income, adjusted |78.7 |73.1 |8% | |
|Net income, adjusted |55.0 |52.5 |5% | |
|EPS, adjusted ($) |0.23 |0.22 | | |

For information on the adjusted figures, please refer to the
reconciliation table accompanying this release.

Net sales rose 7% to $282.2 million in the second quarter of
2011 from $262.7 million in the 2010 quarter. Organic sales rose 1%
CER, while favorable currency movements added an additional
six percentage points to reported sales growth. Operating income
of $46.5 million rose 8% from $42.9 million in the 2010 quarter.
Net income fell 14% to $33.3 million from $38.5 million in the
year-ago period. This year-ago period included a one-time benefit
of $12.0 million (or $0.05 cents per share) from the
restructuring of acquired foreign subsidiaries. Diluted earnings per
share were $0.14 (based on 241.0 million diluted shares) in the 2011
quarter compared to $0.16 in the 2010 quarter (based on 241.6
million diluted shares). Free cash flow increased 31% to $37.8
million.

Adjusted operating income in the second quarter of 2011 rose 8%
to $78.7 million from $73.1 million in the 2010 quarter, while
the adjusted operating income margin maintained at 28% of net
sales. Adjusted net income grew 5% to $55.0 million in the 2011
period from $52.5 million in 2010. Adjusted diluted earnings per
share rose to $0.23 in the 2011 quarter from $0.22 in the second
quarter of 2010.

Reconciliations of reported results in accordance with
U.S. generally accepted accounting principles (GAAP) to adjusted
results are included in the tables accompanying this release.

"Our results in the second quarter of 2011 showed our ability
to deliver year-over-year growth while preserving our profitability
and achieving our adjusted EPS targets amid continued challenging
market conditions," said Roland Sackers, Chief Financial Officer of
QIAGEN N.V. "Our strong financial position supported our M&A
strategy, and we have maintained our strategic flexibility to
strengthen our businesses through sustained R&D investments and
further targeted acquisitions. Our cost controls and targeted
investments in growth opportunities are driving QIAGEN toward
stronger growth rates in the second half of 2011 and into 2012."

First half 2011 Results

| | | |Change
||in $ millions, except per |6M 2011 |6M 2010 |$ |CER
||share information | | | |
||Net sales |546.4 |527.1 |4% |-1%
||Operating income, adjusted |149.2 |146.7 |2% |
||Net income, adjusted |104.5 |101.9 |3% |
||EPS, adjusted ($) |0.43 |0.42 | | |

For information on the adjusted figures, please refer to the
reconciliation table accompanying this release.

Net sales rose 4% to $546.4 million in the first half of 2011
from $527.1 million in the same period of 2010. Organic sales
fell 1% CER, while favorable currency movements contributed five
percentage points to reported sales growth. Operating income of
$84.9 million declined 3% from $87.5 million in the first half of
2010. Net income fell 14% to $61.3 million in the first half of
2011 from $71.5 million in the year-ago period (including the
one-time tax benefit in 2010). Diluted earnings per share were
$0.25 (based on 240.7 million diluted shares) in the first half of
2011 compared to $0.30 in the first half of 2010 (based on 241.8
million diluted shares).

Adjusted operating income in the first half of 2011 rose 2%
to $149.2 million from $146.7 million in the first half of 2010,
with the adjusted operating income margin declining to 27% of net
sales from 28% in the 2010 period. Adjusted net income was up 3% to
$104.5 million in the 2011 period from $101.9 million in the first
half of 2010. Adjusted diluted earnings per share rose to $0.43 in
the first half of 2011 from $0.42 in the first half of 2010.

Reconciliations of reported results in accordance with
U.S. generally accepted accounting principles (GAAP) to adjusted
results are included in the tables accompanying this release.

Business Review

Consumable products delivered single-digit growth in the
second quarter of 2011, but it was partially offset by lower
sales of instruments. Acquisitions completed during the last 12
months did not provide any meaningful sales contributions in the
2011 period. However, fresh growth impulses are anticipated in the
second half of the year from the integration of Ipsogen (full
consolidation with a non-controlling interest as of July 12, 2011)
and Cellestis (closing expected in late August). Both acquisitions
were announced in the second quarter.

Among product categories, consumables and related revenues
provided 88% of sales in the second quarter of 2011, rising 2% CER
from the 2010 period. Instrumentation contributed 12% of sales,
down 7% CER from the year-ago quarter, mainly due to reduced
orders by life sciences customers. Reported instrument sales also
reflect a shift toward greater use of "reagent rental
agreements" and similar arrangements, in which an instrument is
placed at the customer's site in return for a commitment to
purchase consumables over a multi- year period or a regular leasing
fee. Instrument sales from these types of agreements are
recognized pro rata over the life of multi- year agreements.

Among the regions, the Americas (52% of sales) delivered 5%
CER growth in net sales compared to the second quarter of 2010,
while Europe / Middle East / Africa (31% of sales) declined 5%
CER and Asia-Pacific / Japan (17% of sales) rose 8% CER.

The improving performance in the second quarter of 2011 was
enabled by low-single-digit CER sales contributions in most
customer classes:

Molecular Diagnostics (46% of net sales) rose 2% CER in the
second quarter of 2011 as solid growth in consumable products
was reduced by lower instrument sales (due mainly to the shift
to reagent rental agreements). The comparison also was hampered
by higher one-time contributions in the 2010 quarter, which
included payments for companion diagnostic co-development
projects with pharmaceutical companies. Increased sales of HPV
tests in the U.S. drove growth in Prevention as the success of
market conversion initiatives more than offset the negative
impact of reduced patient visits to physicians, which have
declined during 2011.

Applied Testing (7% of net sales) grew 1% CER on strong demand
for consumable products used in implementing new forensic
standards in Europe and other countries as well as human
identification products needed to support disaster recovery
efforts in Japan. Instrument sales were lower compared to the
same period in 2010.

Pharma (21% of net sales) had largely unchanged CER sales, with
growth seen in consumable products used for drug development,
but soft demand in drug discovery and some impact from industry
consolidation and cost-containment measures.

Academia (26% of net sales) rose 1% CER and faced increasing
pressure in some key markets, including Europe and the U.S.,
from the impact of austerity measures and reduced government
spending plans. Higher sales of consumables were offset by
significantly lower instrument sales.

Expansion strategy in 2011 making strides toward accelerating
growth in 2012

QIAGEN took important actions in the second quarter of 2011
to advance a strategy to expand its global leadership in Sample &
Assay Technologies in order to accelerate growth in 2012 and
beyond. Progress came from QIAGEN's continuing commitment to organic
growth through innovation and geographic expansion, as well as
from two targeted acquisitions announced in the 2011 quarter.

Significant achievements have been made during 2011 to
strengthen QIAGEN´s leadership position in Personalized
Healthcare, where QIAGEN's industry-leading presence is driven
by more than 20 molecular diagnostic assays available in select
regions of the world as well as more than 15 co-development
projects under way with pharmaceutical companies.

. The U.S. submission of the therascreen KRAS assay has been
completed for use as a companion diagnostic paired with an
anticancer medicine for the treatment of patients with
metastatic colorectal cancer. This marks the first U.S.
regulatory submission of a companion diagnostic by QIAGEN in
the United States. A second U.S. regulatory submission (PMA)
involving KRAS paired with another anticancer medicine for
treatment of patients with metastatic colorectal cancer is
planned to be completed by the end of July. Several other
programs are under way, including a U.S. submission of an EGFR
biomarker test paired for use with an anticancer medicine in
patients with non-small cell lung cancer that is on track for
completion in 2012.

. QIAGEN significantly added to its portfolio of disease
profiling tests and companion diagnostic candidates through the
acquisition of Ipsogen S.A. (Alternext:ALIPS) in the second
quarter of 2011, which added a global leader in detection and
profiling of leukemia and other blood cancers to the QIAGEN
portfolio. Ipsogen offers a range of assays covering 15
biomarkers, led by an exclusive worldwide license for detection
of the key V617F mutation in the JAK2 gene (Janus kinase 2). In
July, QIAGEN acquired approximately 62.5% of the common shares
of Ipsogen from the founders and certain other shareholders. A
public offer to acquire the remaining shares and gain full
ownership is planned to be completed in 2011.

In addition to the acquisition of Ipsogen, the pending
acquisition of Cellestis Limited (CST:AU) further supports the
strategy of adding molecular content to QIAGEN's broad menu of
tests. In July, key Cellestis shareholders issued public support
for the transaction after QIAGEN amended its original offer, and the
transaction is now expected to be completed in late August.
QIAGEN announced an agreement in April 2011 to fully acquire
Cellestis, which has created a breakthrough "pre-molecular"
technology for diagnosing diseases earlier than is possible with
other diagnostic methods. Cellestis currently markets
QuantiFERON® tests for latent tuberculosis (TB) and the
life-threatening cytomegalovirus (CMV). QIAGEN plans to migrate
QuantiFERON® products onto its automated platforms and develop
new pre-molecular tests that complement QIAGEN's DNA- and
RNA-based molecular diagnostics portfolio.

The QIAsymphony instrumentation platform has now reached more
than 475 installed systems around the world. Global rollout
of QIAsymphony RGQ, the full version of this next-generation
automated modular testing platform, continues to receive positive
feedback from customers. The complete QIAsymphony RGQ version was
launched in late 2010 and builds on the launch of other modules
since 2008. It incorporates the Rotor-Gene Q (RGQ) real-time PCR
detection platform with sample processing and assay setup units,
becoming the first modular system that automates entire
laboratory workflows from initial sample preparation to final
result. QIAGEN believes continued expansion of the QIAsymphony
installed base will drive future growth, particularly in Molecular
Diagnostics.

QIAGEN also is expanding its geographic presence, particularly
in emerging, high-growth regions. During the second quarter of
2011, QIAGEN began direct operations in Taiwan. The beginning of
direct sales in India during the first quarter of 2011 also
deepened QIAGEN's relationships with customers in the Indian life
sciences and biotechnology market, one of the fastest growing in the
region. QIAGEN entered China in 2004 and has expanded to more
than 500 employees in Asia.

2011 outlook (Barring unforeseen events)

QIAGEN has updated its expectations for 2011 based on
acquisitions to be completed this year, as well as the ongoing
challenging market conditions. For the second half of 2011, QIAGEN
expects total sales growth of approximately 7% CER, of which
approximately half is expected to come from organic growth. For the
full year 2011, QIAGEN now expects total sales growth of
approximately 3% CER with contributions from both organic growth
and acquisitions. Adjusted diluted earnings per share (EPS) are
expected to be approximately $0.96 for 2011, which includes
previously announced expectations for dilution of approximately
$0.03 per share related to planned investments and product
migrations as part of the acquisitions of Cellestis and Ipsogen.
(Net sales for 2010 were $1,087 million and adjusted diluted
earnings per share were $0.93.)

Conference Call and Webcast Details

Information on QIAGEN's business and financial performance will
be presented during a conference call on Tuesday, July 26, 2011,
at 9:30 ET / 15:30 CET. The corresponding presentation slides will
be available for download shortly before the conference call
at www.qiagen.com/goto/ConferenceCall, and a webcast is available
at this website. A replay will also be made available on this
website.

Use of Adjusted Results

QIAGEN has regularly reported adjusted results, as well as
results considered on a constant exchange rate basis, to give
additional insight into its financial performance. Adjusted results
should be considered in addition to the reported results
prepared in accordance with generally accepted accounting
principles, but should not be considered as a substitute. The
company believes certain items should be excluded from adjusted
results when they are outside of its ongoing core operations, vary
significantly from period to period, or affect the comparability
of results with the company's competitors and its own prior
periods. Reconciliations of reported results to adjusted results
are included in the tables accompanying this release.

Tables with detailed financial information can be downloaded in
PDF format from:
http://www.qiagen.com/about/investorrelation/aboupdf/Q211_e.pdf

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading
global provider of sample and assay technologies. Sample
technologies are used to isolate and process DNA, RNA and proteins
from biological samples such as blood or tissue. Assay technologies
are used to make these isolated biomolecules visible. QIAGEN
has developed and markets more than 500 sample and assay products
as well as automated solutions for such consumables. QIAGEN
provides its products to molecular diagnostics laboratories,
academic researchers, pharmaceutical and biotechnology
companies, and applied testing customers for purposes such as
forensics, animal or food testing and pharmaceutical process
control. QIAGEN's assay technologies include one of the broadest
panels of molecular diagnostic tests available worldwide. This
panel includes the first FDA-approved test for human papillomavirus
(HPV), the primary cause of cervical cancer. QIAGEN employs nearly
3,600 people in over 30 locations worldwide. Further information
about QIAGEN can be found at http://www.qiagen.com/.

Certain of the statements contained in this news release may
be considered forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1933, as amended, and
Section 21E of the U.S. Securities Exchange Act of 1934, as
amended. To the extent that any of the statements contained
herein relating to QIAGEN's products, markets, strategy or
operating results, including without limitation its expected
operating results, are forward- looking, such statements are
based on current expectations and assumptions that involve a
number of uncertainties and risks. Such uncertainties and risks
include, but are not limited to, risks associated with
management of growth and international operations (including the
effects of currency fluctuations, regulatory processes and
dependence on logistics), variability of operating results and
allocations between customer classes, the commercial development
of markets for our products in applied testing, personalized
healthcare, clinical research, proteomics, women's health/HPV
testing and nucleic acid-based molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including fluctuations
due to general economic conditions, the level and timing of
customers' funding, budgets and other factors); our ability to
obtain regulatory approval of our products; difficulties in
successfully adapting QIAGEN's products to integrated solutions and
producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products, the consummation of the Ipsogen and Cellestis
acquisitions, and the integration of acquired technologies and
businesses. For further information, please refer to the discussions
in reports that QIAGEN has filed with, or furnished to, the U.S.
Securities and Exchange Commission (SEC).

###

|

Contacts:
Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49 2103 29 11826
+1 240 686 7425

Email: pr@qiagen.com

www.twitter.com/qiagen

Investor Relations:
John Gilardi
VP Corporate Communications
+49 2103 29 11711

Dr. Solveigh Maehler
Director Investor Relations
+49 2103 29 11710

Email: ir@qiagen.com